Use: Labeled indications
SmPC 4.1 Therapeutic indications EU SmPC (EMA)
NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in
those undergoing surgery or invasive procedures in the following patient groups:
• in patients with congenital haemophilia with inhibitors to coagulation factors VIII or
IX > 5 Bethesda Units (BU)
• in patients with congenital haemophilia who are expected to have a high anamnestic response to
factor VIII or factor IX administration
• in patients with acquired haemophilia
• in patients with congenital FVII deficiency
• in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet
transfusions, or where platelets are not readily available.Severe postpartum haemorrhage
NovoSeven is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.
Contraindications
SmPC 4.3 Contraindications EU SmPC (EMA)
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to mouse, hamster or bovine protein.
Dosing: Adult
SmPC 4.2 Posology and method of administration EU SmPC (EMA)
Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia and/or bleeding disorders.
In the management of severe postpartum haemorrhage, appropriate multidisciplinary expertise should be consulted. In addition to obstetricians, this includes anaesthesiologists, critical care specialists and/or haematologists. Standard management practices should remain implemented, based on the individual patient’s requirements. Maintenance of adequate fibrinogen concentration and platelet count is recommended in order to optimise the benefit of NovoSeven treatment.
Posology
Haemophilia A or B with inhibitors or expected to have a high anamnestic response
Dose
NovoSeven should be given as early as possible after the start of a bleeding episode. The recommended initial dose, administered by intravenous bolus injection, is 90 μg per kg body weight. Following the initial dose of NovoSeven further injections may be repeated. The duration of treatment and the interval between injections will vary with the severity of the haemorrhage, the invasive procedures or surgery being performed.
Paediatric population
Current clinical experience does not warrant a general differentiation in dosing between children and adults, although children have faster clearance than adults. Therefore, higher doses of rFVIIa may be needed in paediatric patients to achieve similar plasma concentrations as in adult patients (see section 5.2).
Dose interval
Initially 2 – 3 hours to obtain haemostasis. If continued therapy is needed, the dose interval can be increased successively once effective haemostasis is achieved to every 4, 6, 8 or 12 hours for as long as treatment is judged as being indicated.
Mild to moderate bleeding episodes (including home therapy)
Early intervention has been shown to be efficacious in the treatment of mild to moderate joint, muscle and mucocutaneous bleeds. Two dosing regimens can be recommended:
1) Two to three injections of 90 µg per kg body weight administered at three-hour intervals.
If further treatment is required, one additional dose of 90 µg per kg body weight can be
administered.
2) One single injection of 270 µg per kg body weight.The duration of home therapy should not exceed 24 hours. Only after consultation with the haemophilia treatment centre can continued home treatment be considered.
There is no clinical experience with administration of a single dose of 270 µg per kg body weight in elderly patients.
Serious bleeding episodes
An initial dose of 90 µg per kg body weight is recommended and could be administered on the way to the hospital where the patient is usually treated. The following dose varies according to the type and severity of the haemorrhage. Dosing frequency should initially be every second hour until clinical improvement is observed. If continued therapy is indicated, the dose interval can then be increased to 3 hours for 1 – 2 days. Thereafter, the dose interval can be increased successively to every 4, 6, 8 or 12 hours for as long as treatment is judged as being indicated. A major bleeding episode may be treated for 2 – 3 weeks but can be extended beyond this if clinically warranted.
Invasive procedure/surgery
An initial dose of 90 µg per kg body weight should be given immediately before the intervention. The dose should be repeated after 2 hours and then at 2 – 3 hour intervals for the first 24 – 48 hours depending on the intervention performed and the clinical status of the patient. In major surgery, the dose should be continued at 2 – 4 hour intervals for 6 – 7 days. The dose interval may then be increased to 6 – 8 hours for another 2 weeks of treatment. Patients undergoing major surgery may be treated for up to 2 – 3 weeks until healing has occurred.
Acquired Haemophilia
Dose and dose interval
NovoSeven should be given as early as possible after the start of a bleeding episode. The recommended initial dose, administered by intravenous bolus injection, is 90 µg per kg body weight. Following the initial dose of NovoSeven further injections may be given if required. The duration of treatment and the interval between injections will vary with the severity of the haemorrhage, the invasive procedures or the surgery being performed. The initial dose interval should be 2 – 3 hours. Once haemostasis has been achieved, the dose interval can be increased successively to every 4, 6, 8 or 12 hours for as long as treatment is judged to be indicated.
Factor VII deficiency
Dose, dose range and dose interval
The recommended dose range in adults and children for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 15 – 30 μg per kg body weight every 4 – 6 hours until haemostasis is achieved. Dose and frequency of injections should be adapted to each individual.
Paediatric population
Limited clinical experience in long term prophylaxis has been gathered in the paediatric population below 12 years of age, with a severe clinical phenotype (see section 5.1).
Dose and frequency of injections for prophylaxis should be based on clinical response and adapted to each individual.
Glanzmann’s thrombasthenia
Dose, dose range and dose interval
The recommended dose for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 90 µg (range 80 – 120 µg) per kg body weight at intervals of two hours (1.5 – 2.5 hours). At least three doses should be administered to secure effective haemostasis. The recommended route of administration is bolus injection as lack of efficacy may appear in connection with continuous infusion.
For those patients who are not refractory, platelets is the first line treatment for Glanzmann’s thrombasthenia.
Severe postpartum haemorrhage
Dose range and dose interval
The recommended dose range for the treatment of bleeding is 60 – 90 µg per kg body weight administered by intravenous bolus injection. Peak coagulant activity can be expected at 10 minutes. A second dose can be administered based on clinical response of the individual patient. It is recommended that in case of insufficient haemostatic response, a second dose can be administered after 30 minutes.
Method of administration
For instructions on reconstitution of the medicinal product before administration, see section 6.6. Administer the solution as an intravenous bolus injection over 2 – 5 minutes.
Monitoring of treatment – laboratory tests
There is no requirement for monitoring of NovoSeven therapy. Severity of bleeding condition and clinical response to NovoSeven administration must guide dosing requirements.
After administration of rFVIIa, prothrombin time (PT) and activated partial thromboplastin time (aPTT) have been shown to shorten, however no correlation has been demonstrated between PT and aPTT and clinical efficacy of rFVIIa.
Dosing: Altered kidney function
The EU SmPC (EMA) for this generic has no separate kidney-specific text. See SmPC 4.2 and 5.2 below, and the Philippine package insert.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric population (SmPC 4.2) EU SmPC (EMA)
Paediatric population
Current clinical experience does not warrant a general differentiation in dosing between children and adults, although children have faster clearance than adults. Therefore, higher doses of rFVIIa may be needed in paediatric patients to achieve similar plasma concentrations as in adult patients (see section 5.2).
Paediatric population
Limited clinical experience in long term prophylaxis has been gathered in the paediatric population below 12 years of age, with a severe clinical phenotype (see section 5.1).
Dose and frequency of injections for prophylaxis should be based on clinical response and adapted to each individual.
Dosage forms
Philippines
- Powder for solution for injection: 1 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Eptacog alfa as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
NovoSeven RTEptacog alfa (activated) | 1 mg Powder for Solution for Injection (IV)Each box contains: 1 Type I glass vial; 1 Type I pre-filled syringe x 3 mL (solvent); 1 plunger rod; 1 vial adapter | Rx | Novo Nordisk A/SDenmark | Importer: Novo Nordisk Pharmaceuticals (Philippines) Inc. | BR-1282 | Jul 25, 2028 | |
NovoSeven RTEptacog alfa (activated) | 1 mg Powder for Solution for Injection (IV)One (1) box contains: 2 mL Type I glass vial with gray. chlorobutyl rubber stopper and aluminum snap-off cap + 3 mL (Net content: 1 mL) Type I borosilicate pre-filled glass syringe with bromobutyl rubber stopper, and bromobutyl rubber tip cap (Histidine as solvent) + Vial adapter. | Rx | Novo Nordisk A/SDenmark | Novo Nordisk Pharmaceuticals (Philippines), Inc. | BR-1484 | Jul 1, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
SmPC 4.4 Special warnings and precautions for use EU SmPC (EMA)
In pathological conditions in which tissue factor may be expressed more extensively than considered normal, there may be a risk of development of thrombotic events or induction of Disseminated Intravascular Coagulation (DIC) in association with NovoSeven treatment.
Such situations may include patients with advanced atherosclerotic disease, crush injury, septicaemia or DIC. Because of the risk of thromboembolic complications, caution should be exercised when administering NovoSeven to patients with a history of coronary heart disease, to patients with liver disease, to post-operative patients, to pregnant or peripartum women, to neonates, or to patients at risk of thromboembolic events or DIC. In each of these situations, the potential benefit of treatment with NovoSeven should be weighed against the risk of these complications.
In severe postpartum haemorrhage and pregnancy, the clinical conditions (delivery, severe haemorrhage, transfusion, DIC, surgery/invasive procedures and coagulopathy) are known contributing factors to the thromboembolic risk; and in particular venous thromboembolic risk associated with the administration of NovoSeven (see section 4.8).
As recombinant coagulation factor VIIa NovoSeven may contain trace amounts of mouse IgG, bovine IgG and other residual culture proteins (hamster and bovine serum proteins), the remote possibility exists that patients treated with the product may develop hypersensitivity to these proteins. In such cases treatment with antihistamines i.v. should be considered.
If allergic or anaphylactic-type reactions occur, the administration should be discontinued immediately. In case of shock, standard medical treatment for shock should be implemented. Patients should be informed of the early signs of hypersensitivity reactions. If such symptoms occur, the patient should be advised to discontinue use of the product immediately and contact their physician.
In case of severe bleeds the product should be administered in hospitals preferably specialised in treatment of haemophilia patients with coagulation factor VIII or IX inhibitors, or if not possible, in close collaboration with a physician specialised in haemophilia treatment.
If bleeding is not kept under control hospital care is mandatory. Patients/carers should inform the physician/supervising hospital at the earliest possible opportunity about all usages of NovoSeven.
Factor VII deficient patients should be monitored for prothrombin time and factor VII coagulant activity before and after administration of NovoSeven. In case the factor VIIa activity fails to reach the expected level or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed. Thrombosis has been reported in FVII deficient patients receiving NovoSeven during surgery but the risk of thrombosis in factor VII deficient patients treated with NovoSeven is unknown (see section 5.1).
Sodium content
The medicinal product contains less than 1 mmol sodium (23 mg) per injection, indicating that it is essentially ‘sodium free’.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Drug interactions
SmPC 4.5 Interaction with other medicinal products and other forms of interaction EU SmPC (EMA)
The risk of a potential interaction between NovoSeven and coagulation factor concentrates is unknown. Simultaneous use of prothrombin complex concentrates, activated or not, should be avoided.
Antifibrinolytics have been reported to reduce blood loss in association with surgery in haemophilia patients, especially in orthopaedic surgery and surgery in regions rich in fibrinolytic activity, such as the oral cavity. Antifibrinolytics are also used to reduce blood loss in women with postpartum haemorrhage. Experience with concomitant administration of antifibrinolytics and rFVIIa treatment is, however, limited.
Based on a non-clinical study (see section 5.3) it is not recommended to combine rFVIIa and rFXIII. There are no clinical data available on interaction between rFVIIa and rFXIII.
Adverse reactions
SmPC 4.8 Undesirable effects EU SmPC (EMA)
Summary of the safety profile
The most frequently reported adverse drug reactions are decreased therapeutic response, pyrexia, rash, venous thromboembolic events, pruritus and urticaria. These reactions are reported as uncommon (≥ 1/1,000, < 1/100).
Tabulated summary of adverse reactions
Table 1 lists adverse reactions reported during clinical trials and from spontaneous (post-marketing) reports. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Adverse drug reactions reported post-marketing only (i.e. not in clinical trials) are presented with a frequency of ‘not known’.
Clinical trials conducted in 484 patients (including 4297 treatment episodes) with haemophilia A and B, acquired haemophilia, factor VII deficiency or Glanzmann’s thrombasthenia have shown that adverse drug reactions are common (≥ 1/100 to < 1/10). As the total number of treatment episodes in clinical trials is below 10,000, the lowest possible frequency of adverse drug reactions that can be assigned is rare (≥ 1/10,000 to < 1/1,000).
The most frequent adverse drug reactions are pyrexia and rash (uncommon: ≥ 1/1,000 to < 1/100), and the most serious adverse drug reactions include venous thromboembolic events (uncommon: ≥ 1/1,000 to < 1/100) and arterial thromboembolic events (rare: ≥ 1/10,000 to < 1/1,000).
The frequencies of both serious and non-serious adverse drug reactions are listed by system organ classes in the table below
Table 1 Adverse reactions from clinical trials and spontaneous (post-marketing) reports MedDRA system Uncommon (≥1/1,000 to Rare (≥1/10,000 to <1/1,000) Frequency Not Known organ class <1/100) Blood and - Disseminated lymphatic system intravascular coagulation disorders (see section 4.4)
- Related laboratory findings, including elevated levels of D-dimer and decreased levels of AT (see section 4.4)
- Coagulopathy
Gastrointestinal - Nausea
disorders
General disorders - Therapeutic response - Injection site reaction
and decreased* including injection site
administration pain
site conditions - Pyrexia
Immune system - Hypersensitivity (see - Anaphylactic reaction
disorders sections 4.3 and 4.4)
Investigations - Increased fibrin
degradation products- Increase of alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase and prothrombin
Nervous system - Headache
disorders
Skin and - Rash (including - Flushing
subcutaneous allergic dermatitis and
tissue disorders rash erythematous) - Angioedema
- Pruritus and urticaria
Vascular - Venous - Arterial thromboembolic - Intracardiac thrombus
disorders thromboembolic events (myocardial
events (deep vein infarction, cerebral
thrombosis, infarction, cerebral
thrombosis at i.v. site, ischaemia, cerebral
pulmonary embolism, artery occlusion,
thromboembolic cerebrovascular accident,
events of the liver renal artery thrombosis,
including portal vein peripheral ischaemia,
thrombosis, renal vein peripheral arterial
thrombosis, thrombosis and intestinal
thrombophlebitis, ischaemia)
superficial
thrombophlebitis and - Angina pectoris
intestinal ischaemia)- Lack of efficacy (therapeutic response decreased) has been reported. It is important that the dosage regimen of NovoSeven is compliant with the recommended dosage as stated in section 4.2.
Description of selected adverse reactions
Inhibitory antibody formation
In post-marketing experience, there have been no reports of inhibitory antibodies against NovoSeven or FVII in patients with haemophilia A or B. Development of inhibitory antibodies to NovoSeven has been reported in a post-marketing observational registry of patients with congenital FVII deficiency.
In clinical trials of patients with factor VII deficiency, formation of antibodies against NovoSeven and FVII is the only adverse drug reaction reported (frequency: common (≥ 1/100 to < 1/10)). In some cases, the antibodies showed inhibitory effect in vitro. Risk factors that may have contributed to antibody development including previous treatment with human plasma and/or plasma-derived factor VII, severe mutation of FVII gene, and overdose of NovoSeven, were present. Patients with factor VII deficiency treated with NovoSeven should be monitored for factor VII antibodies (see section 4.4).
Thromboembolic events - arterial and venous
When NovoSeven is administered to patients outside approved indications, arterial thromboembolic events are common (≥ 1/100 to < 1/10). A higher risk of arterial thromboembolic adverse events (see table: Vascular disorders) (5.6% in patients treated with NovoSeven versus 3.0% in placebo-treated patients) has been shown in a meta-analysis of pooled data from placebo-controlled trials conducted outside current approved indications in various clinical settings, each of these having distinct patient characteristics and hence different underlying risk profiles.
Safety and efficacy of NovoSeven have not been established outside the approved indications and therefore NovoSeven should not be used.
Thromboembolic events may lead to cardiac arrest.
Other special populations
Patients with acquired haemophilia
Clinical trials conducted in 61 patients with acquired haemophilia with a total of 100 treatment episodes, showed that certain adverse drug reactions were reported more frequently (1% based on treatment episodes): Arterial thromboembolic events (cerebral artery occlusion, cerebrovascular accident), venous thromboembolic events (pulmonary embolism and deep vein thrombosis), angina pectoris, nausea, pyrexia, erythematous rash and investigation of increased levels of fibrin degradation products.
Women with severe postpartum haemorrhage
In an open-label randomised clinical trial, venous thromboembolic events were reported in 2 of 51 patients treated with a single dose of NovoSeven (median dose 58 μg/kg) and none of 33 patients not treated with NovoSeven; no arterial thromboembolic events were reported in either group. In 4 non-interventional studies, venous thromboembolic events were reported in 3 of 358 (0.8%) patients treated with NovoSeven (median dose range 63-105 µg/kg) and arterial thromboembolic events were reported in 1 (0.3%) patient treated with NovoSeven.
For known contributing factors to thromboembolic risk associated with pregnancy and severe postpartum haemorrhage, see section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Pregnancy considerations
SmPC 4.6 Fertility, pregnancy and lactation EU SmPC (EMA)
Pregnancy
As a precautionary measure, it is preferable to avoid use of NovoSeven during pregnancy. Data on a limited number of exposed pregnancies within approved indications indicate no adverse effects of rFVIIa on pregnancy or on the health of the foetus/new-born child. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Breast-feeding
It is unknown whether rFVIIa is excreted in human breast milk. The excretion of rFVIIa in milk has not been studied in animals. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with NovoSeven should be made taking into account the benefit of breast-feeding to the child and the benefit of NovoSeven therapy to the woman.
Fertility
Data from non-clinical studies as well as post-marketing data show no indication that rFVIIa has a harmful effect on male or female fertility.
Breastfeeding considerations
Breastfeeding is covered in SmPC 4.6 Fertility, pregnancy and lactation, under Pregnancy considerations above.
Overdose
SmPC 4.9 Overdose EU SmPC (EMA)
Dose limiting toxicities of NovoSeven have not been investigated in clinical trials.
Four cases of overdose have been reported in patients with haemophilia in 16 years. The only complication reported in connection with an overdose was a slight transient increase in blood pressure in a 16 year-old patient receiving 24 mg rFVIIa instead of 5.5 mg.
No cases of overdose have been reported in patients with acquired haemophilia or Glanzmann’s thrombasthenia.
In patients with factor VII deficiency, where the recommended dose is 15 – 30 µg/kg rFVIIa, one episode of overdose has been associated with a thrombotic event (occipital stroke) in an elderly (> 80 year) male patient treated with 10 – 20 times the recommended dose. In addition, the development of antibodies against NovoSeven and FVII has been associated with overdose in one patient with factor VII deficiency.
The dose schedule should not be intentionally increased above the recommended doses due to the absence of information on the additional risk that may be incurred.
Mechanism of action
SmPC 5.1 Pharmacodynamic properties EU SmPC (EMA)
Pharmacotherapeutic group: Blood coagulation factors, ATC code: B02BD08
Mechanism of action
NovoSeven contains activated recombinant coagulation factor VII. The mechanism of action includes the binding of factor VIIa to exposed tissue factor. This complex activates factor IX into factor IXa and factor X into factor Xa, leading to the initial conversion of small amounts of prothrombin into thrombin. Thrombin leads to the activation of platelets and factors V and VIII at the site of injury and to the formation of the haemostatic plug by converting fibrinogen into fibrin. Pharmacological doses of NovoSeven activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.
Pharmacodynamic effects
The pharmacodynamic effect of factor VIIa gives rise to an increased local formation of factor Xa, thrombin and fibrin.
The time to peak coagulant activity after administration of NovoSeven was approximately 10 minutes in healthy subjects and patients with haemophilia.
A theoretical risk for the development of systemic activation of the coagulation system in patients suffering from underlying diseases predisposing them to DIC cannot be totally excluded.
Clinical efficacy and safety
Congenital FVII deficiency
In an observational registry (F7HAEM-3578) covering subjects with congenital FVII deficiency, the median dose for long term prophylaxis against bleeding in 22 paediatric patients (below 12 years of age) with Factor VII deficiency and a severe clinical phenotype was 30 µg/kg (range 17 µg/kg to 200 µg/kg; the dose most often used was 30 µg/kg in 10 patients) with a median dose frequency of 3 doses per week (range 1 to 7; the dose frequency most often reported was 3 per week in 13 patients).
In the same registry 3 out of 91 surgical patients experienced thromboembolic events.
Glanzmann’s thrombasthenia
An observational registry (F7HAEM-3521) covered 133 subjects with Glanzmann’s thrombasthenia treated with NovoSeven. The median dose per infusion for treatment of 333 bleeding episodes was 90 µg/kg (range 28 to 450 µg/kg). NovoSeven was used in 157 surgical procedures, at a median dose of 92 µg/kg (up to 270 µg/kg). Treatment with NovoSeven, alone or in combination with antifibrinolytics and/or platelets, was defined as effective when bleeding was stopped for at least 6 hours. The efficacy rates were 81% and 82%, respectively, in patients with positive or negative refractoriness to platelet transfusions, and 77% and 85%, respectively, in patients testing positive or negative for antibodies to platelets. Positive status indicates at least one positive test at any admission.
Severe postpartum haemorrhage
The efficacy and safety of NovoSeven was assessed in 84 women with severe postpartum haemorrhage in a multicentre, open-label clinical trial. Patients were randomised either to treatment with a single dose of 60 µg/kg of NovoSeven (in addition to standard of care; N=42) or to reference therapy (standard of care alone; N=42), following failure of uterotonics (sulprostone). The treatment groups were well balanced in terms of demographic characteristics and postpartum haemorrhage treatment prior to randomisation. Fibrinogen and tranexamic acid were part of standard of care. Information on fibrinogen/tranexamic acid use was available from approximately 57% of patients in the NovoSeven group and 43% of patients in the reference group. Of these, about 40% of the patients in both groups received fibrinogen and/or tranexamic acid. Bleeding was considered to have stopped (i.e. treatment success) if the estimated blood flow decreased to less than 50 ml per 10 minutes within the 30 minutes following randomisation. If the bleeding was uncontrolled or intractable, invasive procedures were considered.
In the primary analysis, fewer women in the NovoSeven group (21 vs 35) had at least one embolisation and/or ligation procedure compared to the reference group, corresponding to a statistically significant 40% relative reduction in risk for the NovoSeven group compared to the reference group (relative risk = 0.60 (95% confidence interval: 0.43 – 0.84, p=0.0012)).
In the reference group, 8 of the 42 patients received late NovoSeven as a compassionate treatment in an attempt to avoid salvage hysterectomy, which succeeded in 2 cases.
Pharmacokinetics
SmPC 5.2 Pharmacokinetic properties EU SmPC (EMA)
Healthy subjects
Distribution, elimination and linearity
Using the FVII clotting assay, the pharmacokinetics of rFVIIa were investigated in 35 healthy Caucasian and Japanese subjects in a dose-escalation study. Subjects were stratified according to sex and ethnic group and dosed with 40, 80 and 160 µg rFVIIa per kg body weight (3 doses each) and/or placebo. The pharmacokinetics were similar across sex and ethnic groups. The mean steady state volume of distribution ranged from 130 to 165 ml/kg, the mean values of clearance ranged from 33.3 to 37.2 ml/h×kg.
The mean terminal half-life ranged from 3.9 to 6.0 hours. The pharmacokinetic profiles indicated dose proportionality.
Haemophilia A and B with inhibitors
Distribution, elimination and linearity
Using the FVIIa assay, the pharmacokinetic properties of rFVIIa were studied in 12 paediatric (2 – 12 years) and 5 adult patients in non-bleeding state. Mean volume of distribution at steady state was 196 ml/kg in paediatric patients versus 159 ml/kg in adults. Mean clearance was approximately 50% higher in paediatric patients relative to adults (78 versus 53 ml/h×kg), whereas the mean terminal half-life was determined to 2.3 hours in both groups. Clearance appears related with age, therefore in younger patients clearance may be increased by more than 50%. Dose proportionality was established in children for the investigated doses of 90 and 180 µg per kg body weight, which is in accordance with previous findings at lower doses (17.5 – 70 µg/kg rFVIIa).
Factor VII deficiency
Distribution and elimination
Single dose pharmacokinetics of rFVIIa, 15 and 30 μg per kg body weight, showed no significant difference between the two doses used with regard to dose-independent parameters: Volume of distribution at steady state (280 – 290 ml/kg), half-life (2.82 – 3.11 h), total body clearance (70.8 – 79.1 ml/h×kg) and mean residence time (3.75 – 3.80 h). The mean in vivo plasma recovery was approximately 20%.
Glanzmann’s thrombasthenia
Pharmacokinetics of NovoSeven in patients with Glanzmann’s thrombasthenia have not been investigated, but are expected to be similar to the pharmacokinetics in haemophilia A and B patients.
Severe postpartum haemorrhage
Pharmacokinetics of NovoSeven in patients with severe postpartum haemorrhage have not been investigated.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- European Medicines Agency. NovoSeven: EPAR, product information, Annex I, Summary of Product Characteristics [EU SmPC, last updated January 5, 2023; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven © European Medicines Agency; reproduced with acknowledgment of the source.
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .